NORYVA
The one whose work covers the widest range of tissues.
10 mg
BPC-157 is a short sequence, rebuilt from a piece of a protein the stomach makes. What drew attention is not one tissue in particular: in animals, the same sequence keeps coming back on gut, tendon and muscle.
The same reference, in pen format
The molecule is delivered in a sealed cartridge, inside a refillable anodised aluminium pen. It is not an accessory to add on: it is the other way of ordering the same reference, at its own price.
If it is so promising, why is there almost nothing in humans?
That is the right question, and the answer is short: there is almost nothing. Controlled human data are extremely limited, and the literature comes from a small number of laboratories. We write it here rather than let you find it elsewhere.
What drew attention is not one spectacular result on one tissue, it is the CONSISTENCY: in animals, the same sequence acts on the repair of tissues that have nothing in common. It is a serious lead, and it is also all that can be said: controlled human data are extremely limited.
BPC-157 is a synthetic fifteen-amino-acid peptide derived from a sequence identified in a human gastric juice protein. It does not exist as such in the body: it is a reconstructed fragment.
It is studied for its observed effect on healing across varied tissues in animal models — tendon, muscle, intestine — with a consistency that has drawn attention.
Proposed mechanism: influence on the formation of new blood vessels, notably via the VEGF pathway, and interaction with the nitric oxide system. The mechanism is not established; several pathways are proposed without any commanding consensus.
This is the central point and it must be stated plainly: published, controlled human data are extremely limited. Almost all of the available literature concerns rodents. A heavily cited molecule is not a molecule demonstrated in humans.
Abundant animal literature, coming largely from a small number of groups — which limits the value of the repeated findings.
Absence of solid controlled human data. Concentration of publications in few laboratories. No long-term human safety assessment. BPC-157 has been the subject of authority decisions concerning its use in compounding: those decisions are not approvals and must be read for what they are — see the Science Center.
For laboratory research purposes only. Not for human consumption or therapeutic use.
This reference holds no marketing authorisation as a medicinal product.
No. This reference is not offered for sale: its commercial framework is not settled. No purchase button is shown until it is.
No. This reference holds no marketing authorisation as a medicinal product and is approved by no authority for human use. A publication or a clinical trial never amounts to approval.
The certificate of analysis is supplied with the batch delivered. No batch number or purity figure is published until the real certificate has been entered: we do not display illustrative values.
The storage requirement is not yet on file: the supplier data sheet has not reached us. We would rather say so than assume.
Compatibility is not confirmed for this reference. Until the manufacturer confirms it, we do not claim it.
Absence of solid controlled human data. Concentration of publications in few laboratories. No long-term human safety assessment. BPC-157 has been the subject of authority decisions concerning its use in compounding: those decisions are not approvals and must be read for what they are — see the Science Center.
Conversion not published
How a graduation on the NORYVA pen maps to a volume depends on its mechanism. Its technical sheet is not on file: no conversion is shown until the manufacturer confirms it. We would rather write that than assume it.